- Companies
- Asher Bio
Asher Bio Funding, Investors & Competitors
Asher Bio has raised $218M across 4 funding rounds, most recently a $55M Series C in April 2024.
Last Asher Bio funding round
$55M
Series C · Apr 2024
Cumulative funding Asher Bio raised
$218M
across 4 funding rounds
Key investors in Asher Bio
Third Rock Ventures
Boxer Capital
Y Combinator
RA Capital Management
Wellington Management
Invus
Janus Henderson
Alexandria Venture Investments
About Asher Bio
Asher Bio is a South San Francisco-headquartered biotechnology company developing T cell immunotherapies for cancer. Its ABS-101 program targets autoimmune diseases using half-life extended cytokines, advancing to Phase 1 trials in 2023. Founded in 2019, Asher Bio raised $94 million in Series A funding from investors like Sanofi Ventures and Norwest. The company employs 80 scientists working on precision immunology platforms with engineered T cells.
Founded
2019
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales, Subscription
Asher Bio Funding History
Asher Bio has raised a total of $218M across 4 funding rounds.
Asher Bio's first fundraising round was a $200K pre-seed round in August 2019. The most recent completed round was a $55M Series C in April 2024.
Asher Bio funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Apr 2024 | Series C | RA Capital Management (lead); Boxer Capital; Wellington Management; AstraZeneca; Third Rock Ventures; Janus Henderson; Bristol-Myers Squibb | $55M | Asher Biotherapeutics is a South San Francisco-based biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases. The company's core platform uses cis-targeting to enable selective activation of specific immune cell types, with its lead program AB248 being a CD8-targeted IL-2 immunotherapy designed to maximize efficacy while limiting off-target toxicities. On April 16, 2024, Asher Bio closed a $55 million Series C funding round led by RA Capital Management with participation from new investors AstraZeneca and Bristol Myers Squibb, alongside existing investors including Third Rock Ventures, Wellington Management, Janus Henderson Investors, Boxer Capital, and other undisclosed institutional investors. The Series C financing was intended to advance AB248 through Phase 1b monotherapy expansion and initial combination studies with pembrolizumab, a PD-1 checkpoint inhibitor. As a clinical-stage biotechnology company, Asher Bio has not disclosed public revenue or EBITDA figures; the company was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and had raised a cumulative $218.64 million across five rounds by the Series C closing. |
| Sep 2021 | Series B | Wellington Management (lead); Boxer Capital; Alexandria Venture Investments; Invus; Marshall Wace; Third Rock Ventures; Janus Henderson; Logos Capital; RA Capital Management; Mission BioCapital | $108M | Asher Biotherapeutics is a South San Francisco-based biotechnology company developing precisely-targeted immunotherapies using its cis-targeting platform for cancer, autoimmune, and infectious diseases. The company closed an oversubscribed $108 million Series B financing on September 1, 2021, led by Wellington Management Company LLP, with participation from new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace, Alexandria Venture Investments, and existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and others. Proceeds were allocated to fund lead program AB248, a CD8-targeted IL-2 immunotherapy, through clinical proof-of-concept, advance a second program to IND-enabling studies, and invest in the platform. Prior to the Series B, Asher Bio raised $55 million in a Series A round in March 2021. The Series B matched the size of a competitor's round in the cytokine therapeutic space, Synthekine, which also focused on selective IL-2 agonists. In April 2024, Asher Bio raised $55 million in a Series C led by RA Capital Management, with new investors AstraZeneca and Bristol Myers Squibb, alongside existing backers including Janus Henderson Investors, Third Rock Ventures, and Wellington Management, to advance AB248 into Phase 1b trials. The company later entered an agreement with AstraZeneca to supply etakafusp alfa (AB248) for combination studies with rilvegostomig. |
| Mar 2021 | Series A | Third Rock Ventures (lead); Boxer Capital; Y Combinator; Invus; MBC BioLabs | $55M | Asher Biotherapeutics launched on March 23, 2021, with a $55 million Series A financing led by Third Rock Ventures, with participation from Boxer Capital of Tavistock Group, Invus, Y Combinator, and MBC Biolabs. The company is developing precisely targeted immunotherapies for cancer and other diseases using a novel cis-targeting technology platform that selectively activates specific immune cell types to address limitations of traditional immunotherapies. The financing supports discovery and development efforts, including advancing the lead oncology program AB248, a cis-targeted IL-2 immunotherapy, into clinical trials planned for 2022, along with a pipeline featuring a CAR-T selective IL-2, a T-cell targeted STAT3 activator for cancer, and a Treg-targeted cytokine for autoimmune diseases. The company was founded with support from Third Rock Ventures and is headquartered in South San Francisco. Leadership includes a team assembled around academic founders Ton Schumacher and Robert Schreiber, with statements from Third Rock partners Jeffrey Tong and Reid Huber highlighting the platform's breakthrough potential in cytokine immunotherapy. Subsequent rounds include a $108 million Series B in September 2021 led by Wellington Management with existing investors like Third Rock and Boxer Capital, and a $55 million Series C in April 2024. |
| Aug 2019 | Pre-seed | Y Combinator (lead); Evan Cheng; Alice Zhang | $200K | - |
Who has invested in Asher Bio?
16 investors have backed Asher Bio across its funding rounds, including Third Rock Ventures, Boxer Capital, Y Combinator, RA Capital Management, Wellington Management and Invus.
Lead investors include RA Capital Management, Wellington Management, Third Rock Ventures and Y Combinator.
Asher Bio Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Participant | Mar 2021 | ||
| 3 | Lead | Mar 2021 | ||
| 2 | Lead | Sep 2021 | ||
| 2 | Lead | Aug 2019 | ||
| 2 | Participant | Mar 2021 | ||
| 2 | Participant | Sep 2021 | ||
| 2 | Lead | Sep 2021 | ||
| 1 | Participant | Sep 2021 | ||
| 1 | Participant | Apr 2024 | ||
| 1 | Participant | Sep 2021 | ||
| 1 | Participant | Aug 2019 | ||
| 1 | Participant | Apr 2024 | ||
| 1 | Participant | Sep 2021 | ||
This data is available for Pro users. Sign up to see all 16 Asher Bio investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAsher Bio Competitors
Asher Bio competitors include listed companies like IQVIA, Veeva, IDEXX Laboratories and Roper Technologies, and private ones like Commure and Doctolib.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $16B | $3.4B | $44B | 3.4x | ||
| Publicly listed | $3.2B | $965M | $43B | 10.2x | ||
| Publicly listed | $4.3B | $1.5B | $40B | 8.9x | ||
| Publicly listed | $7.9B | $3.2B | $37B | 5.7x | ||
| Private | $200M | - | $7B | 35.0x | ||
| Private | $400M | - | $6.4B | 16.0x |
Asher Bio Public Comps
Asher Bio is still privately-owned, but its public comps include IQVIA, Veeva, IDEXX Laboratories, Roper Technologies, GE HealthCare, ICON plc, Pro Medicus, United Imaging, Glaukos and M3 Inc..
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $16B | $3.4B | 3.6x | 3.4x | 17.2x | 14.8x | |||
| $3.2B | $965M | 11.1x | 10.2x | 36.9x | 22.4x | |||
| $4.3B | $1.5B | 9.5x | 8.9x | 27.1x | 24.9x | |||
| $7.9B | $3.2B | 6.1x | 5.7x | 15.2x | 14.6x | |||
| $21B | $3.7B | 1.8x | 1.8x | 10.1x | 10.0x | |||
| $8.3B | $816M | 1.9x | 1.9x | 19.2x | 11.3x | |||
| $186M | $147M | 66.6x | 62.7x | 84.4x | 77.6x | |||
| $2.1B | $367M | 5.5x | 4.8x | 30.7x | 26.9x | |||
This data is available for Pro users. Sign up to see all Asher Bio competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Asher Bio
| When was Asher Bio founded? | Asher Bio was founded in 2019. |
| Where is Asher Bio headquartered? | Asher Bio is headquartered in San Francisco, CA, United States. |
| Is Asher Bio publicly listed? | No, Asher Bio is a private, VC-backed company. |
| How much funding has Asher Bio raised? | Asher Bio has raised $218M across 4 funding rounds. |
| What was Asher Bio's last funding round? | Asher Bio's last funding round was a $55M Series C in April 2024, led by RA Capital Management. |
| Who are Asher Bio's investors? | Asher Bio's investors include Boxer Capital, Third Rock Ventures, Wellington Management, Y Combinator, Invus, Janus Henderson, RA Capital Management, Alexandria Venture Investments, AstraZeneca, Marshall Wace and 6 others. |
| Which companies are comparable to Asher Bio? | Companies comparable to Asher Bio include IQVIA, Veeva, IDEXX Laboratories, Roper Technologies, Commure and Doctolib. |
See companies similar to Asher Bio
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




